IT1256692B - Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico. - Google Patents

Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.

Info

Publication number
IT1256692B
IT1256692B ITTO920189A ITTO920189A IT1256692B IT 1256692 B IT1256692 B IT 1256692B IT TO920189 A ITTO920189 A IT TO920189A IT TO920189 A ITTO920189 A IT TO920189A IT 1256692 B IT1256692 B IT 1256692B
Authority
IT
Italy
Prior art keywords
therapeutic use
von willebrand
high purity
industrial scale
willebrand factor
Prior art date
Application number
ITTO920189A
Other languages
English (en)
Italian (it)
Inventor
Miryana Burnouf-Radosevich
Thierry Burnouf
Original Assignee
Centre Regional De Transfusion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Regional De Transfusion filed Critical Centre Regional De Transfusion
Publication of ITTO920189A0 publication Critical patent/ITTO920189A0/it
Publication of ITTO920189A1 publication Critical patent/ITTO920189A1/it
Application granted granted Critical
Publication of IT1256692B publication Critical patent/IT1256692B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ITTO920189A 1991-03-08 1992-03-06 Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico. IT1256692B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9102804A FR2673632A1 (fr) 1991-03-08 1991-03-08 Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (3)

Publication Number Publication Date
ITTO920189A0 ITTO920189A0 (it) 1992-03-06
ITTO920189A1 ITTO920189A1 (it) 1993-09-06
IT1256692B true IT1256692B (it) 1995-12-12

Family

ID=9410505

Family Applications (1)

Application Number Title Priority Date Filing Date
ITTO920189A IT1256692B (it) 1991-03-08 1992-03-06 Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.

Country Status (29)

Country Link
US (1) US5408039A (2)
EP (1) EP0503991B1 (2)
JP (1) JP3435668B2 (2)
AT (1) AT407115B (2)
AU (1) AU645172B2 (2)
BE (1) BE1004178A3 (2)
BR (1) BR9200770A (2)
CA (1) CA2062340C (2)
CZ (1) CZ283633B6 (2)
DE (2) DE122009000034I2 (2)
DK (1) DK0503991T3 (2)
EE (1) EE03057B1 (2)
EG (1) EG20300A (2)
ES (1) ES2121830T3 (2)
FI (1) FI106721B (2)
FR (1) FR2673632A1 (2)
HU (1) HU215098B (2)
IL (1) IL101043A (2)
IT (1) IT1256692B (2)
LT (1) LT3175B (2)
NL (1) NL300394I1 (2)
NO (1) NO301278B1 (2)
NZ (1) NZ241701A (2)
PL (1) PL168353B1 (2)
RU (1) RU2088590C1 (2)
SA (1) SA92120446B1 (2)
SK (1) SK279533B6 (2)
UA (1) UA27732C2 (2)
ZA (1) ZA921430B (2)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) * 1994-10-04 2008-02-07 Immuno Ag Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) * 1995-11-10 1997-05-15 Immuno Ag Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT404358B (de) 1997-02-04 1998-11-25 Immuno Ag Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de) 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
RU2200028C2 (ru) * 2000-06-20 2003-03-10 Кировский НИИ гематологии и переливания крови Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) 2004-08-16 2006-11-03 Lab Francais Du Fractionnement Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
DE102004044419B4 (de) 2004-09-14 2010-04-15 Biotest Ag Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
ITLU20070007A1 (it) * 2007-05-07 2008-11-08 Kedrion Spa Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
JP2010529155A (ja) 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
FR2920429B1 (fr) * 2007-08-30 2012-10-05 Lfb Biotechnologies Procede de purification du facteur viii et du facteur von willebrand
EP2073015A1 (en) 2007-12-21 2009-06-24 CSL Behring GmbH Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
US20100273206A1 (en) * 2007-12-21 2010-10-28 Manfred Rauh Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
IT1396528B1 (it) 2009-01-19 2012-12-14 Kedrion Spa Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
WO2011020866A2 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
SG191186A1 (en) 2010-12-15 2013-07-31 Baxter Int Eluate collection using conductivity gradient
WO2013057167A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii
JP6029674B2 (ja) 2011-10-18 2016-11-24 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
WO2013120939A1 (en) 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
CN105705516B (zh) * 2013-11-08 2019-11-01 杰特有限公司 浓缩von Willebrand因子或其络合物的方法
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
US10626164B2 (en) 2014-07-25 2020-04-21 Csl Limited Purification of VWF
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
US10809247B2 (en) * 2015-10-15 2020-10-20 Plasma Technologies, Llc Methods for extracting proteins from blood plasma
RU2018128613A (ru) 2016-01-07 2020-02-07 Цсл Беринг Ленгнау Аг Мутированный фактор фон виллебранда
DK3400002T3 (da) 2016-01-07 2022-04-11 CSL Behring Lengnau AG Muteret, trunkeret von willebrand faktor
CN105541997A (zh) * 2016-02-04 2016-05-04 江西博雅生物制药股份有限公司 一种高纯度和高活性血管性血友病因子的制备工艺
CN105622746A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
CN105622747A (zh) * 2016-02-04 2016-06-01 江西博雅生物制药股份有限公司 一种vWF活性保护液
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) * 2020-09-22 2023-09-15 四川远大蜀阳药业有限责任公司 一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166542A (ja) * 1985-01-18 1986-07-28 Hitachi Chem Co Ltd 感光性組成物
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US5006642A (en) * 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

Also Published As

Publication number Publication date
FR2673632B1 (2) 1995-05-05
CA2062340A1 (fr) 1992-09-09
NO920867D0 (no) 1992-03-05
DK0503991T3 (da) 1999-06-14
FI920992A0 (fi) 1992-03-06
CS56892A3 (en) 1992-09-16
JPH0597696A (ja) 1993-04-20
AU645172B2 (en) 1994-01-06
HU9200767D0 (en) 1992-05-28
FI920992L (fi) 1992-09-09
NO301278B1 (no) 1997-10-06
HUT63176A (en) 1993-07-28
EE03057B1 (et) 1997-12-15
LTIP266A (en) 1994-07-15
ITTO920189A0 (it) 1992-03-06
ES2121830T3 (es) 1998-12-16
LT3175B (en) 1995-02-27
DE69227055T2 (de) 1999-04-22
UA27732C2 (uk) 2000-10-16
EP0503991B1 (fr) 1998-09-23
NO920867L (no) 1992-09-09
IL101043A (en) 1997-02-18
NZ241701A (en) 1994-10-26
CA2062340C (fr) 2000-05-09
NL300394I1 (nl) 2009-09-01
JP3435668B2 (ja) 2003-08-11
EP0503991A1 (fr) 1992-09-16
ITTO920189A1 (it) 1993-09-06
ZA921430B (en) 1992-11-25
BE1004178A3 (fr) 1992-10-06
AT407115B (de) 2000-12-27
EG20300A (fr) 1998-10-31
FR2673632A1 (fr) 1992-09-11
IL101043A0 (en) 1992-11-15
BR9200770A (pt) 1992-11-17
DE122009000034I1 (de) 2010-04-08
ATA43692A (de) 2000-05-15
DE122009000034I2 (de) 2011-06-16
SA92120446B1 (ar) 2004-05-04
DE69227055D1 (de) 1998-10-29
RU2088590C1 (ru) 1997-08-27
PL168353B1 (pl) 1996-02-29
CZ283633B6 (cs) 1998-05-13
PL293738A1 (en) 1992-09-21
US5408039A (en) 1995-04-18
HU215098B (hu) 1998-09-28
AU1113192A (en) 1992-09-10
FI106721B (fi) 2001-03-30
SK279533B6 (sk) 1998-12-02

Similar Documents

Publication Publication Date Title
IT1256692B (it) Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.
GB9200117D0 (en) Production of recombinant chimeric proteins for vaccine use
DK0547932T3 (da) Fremgangsmåde til fremstilling af et koncentrat af aktiveret faktor VII med høj renhed
ATE183515T1 (de) Zusammensetzungen die die hiv replikation inhibieren
CA2293806A1 (en) Alpha 1-antitrypsin preparation as well as a method for producing the same
ATE192037T1 (de) Verwendung von arginin als immunstimulator
DE3785066D1 (de) Peptide der cholecystokinin-cerulein-gruppe enthaltende pharmazeutische zusammensetzungen zur behandlung von respiratorischen und herz-kreislauf-insuffizienzen.
EA199700256A1 (ru) Выделенные последовательности днк, кодирующие капсидные белки l1 и l2 папилломавируса человека типа 18, вектор для экспресси последовательностей днк, способ получения вирусоподобных частиц и способ индуцирования иммунного ответа
MX9302279A (es) Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.
EP0263761A3 (en) Non-a, non-b, hepatitis antigen
CA2218561A1 (en) Compounds and methods of use to treat infectious diseases
DE69211414D1 (de) Reaktive Behandlung zusammengesetzter Gastrennungsmembranen
AU633925B2 (en) Process for the preparation of purified albumin solutions
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
EP0621788A4 (en) Hemoregulatory peptides.
CA2178208A1 (en) Purification of vitamin-k dependent proteins by membrane chromatography
AU1604592A (en) New 2-amino-5-cyano-1,4-dihydropyridines, processes for their preparation and their use in medicaments
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
EP0378432A3 (en) Novel peptides, their use to inhibit the maturation of t-lymphocytes and the activity of macrophages, and processes for their preparation
CA2096888A1 (en) Process for the inactivation of viruses in preparations of proteins
NO965556L (no) Trippelkombinasjon mot HIV
EP0963441A4 (en) INACTIVATION OF HIV CO-RECEPTORS FOR THE THERAPY OF HIV INFECTION
NZ256246A (en) Serine leukocyte protease inhibitor, recombinant preparation thereof, and treatment of a retroviral infection
HUP0100937A2 (hu) Többszörösen elágazó peptidkonstrukciókat tartalmazó liposzómák és alkalmazásuk humán immundeficiencia vírus ellen
ITFI930260A1 (it) Processo per l'estrazione e purificazione dell'alfal-antitripsina (alfal-pi)dalla frazione iv-1 di cohn.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19990331